GLP & efficacy/investigative assessment studies are available at Covance.

1. DRUG ABUSE-RELATED STUDIES
Supporting your investigative, efficacy,
and GLP regulatory requirements
GLP Regulatory Studies
Regulatory agencies require that any drug (parent or major metabolite)
that penetrates the brain and has CNS activity, regardless of its
therapeutic indication, be assessed for that drug’s abuse/dependence
potential. The following rodent nonclinical, fully GLP compliant studies
are conducted at Covance:
Investigative/Efficacy Studies
In addition to our GLP regulatory portfolio of studies, we support your early investigative work by
evaluating compounds for potential abuse risk; testing the efficacy of drugs to prevent or treat drug-use
disorders; and assessing the analgesic activity of drugs for pain relief.
A Nimble, Agile and Experienced Partner
Understanding the different study types, time-lines and logistics involved in the assessment of abuse
potential for novel drugs can be challenging. Our experienced team will partner with you to provide
additional expertise, time and capacity to support your program.
Investigative/Efficacy Studies
Pain Models
(Other tests are available upon request)
▶ Self-administration cue reinstatement
▶ Drug-induced behavioral sensitization
▶ Cannabinoid tetrad
▶ Tail flick
▶ Abdominal spasm
▶ Randall-Selitto
GLP Drug Abuse/Dependence Liability Studies
▶ Self-administration
▶ Drug discrimination
▶ Physical dependency
▶ Bioanalysis and formulation
analysis
▶ Consultancy services are
available
Regulatory
submission
Safety Efficacy
Learn more at www.covance.com/drug-abuse
Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory
Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the
marketing name for Covance Inc. and its subsidiaries around the world.
The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440
Europe / Africa +00.800.2682.2682 +44.1423.500888
Asia Pacific +800.6568.3000 +65.6.5686588
© Copyright 2018 Covance Inc. SSTOX029-0818
Let’s Partner, Together.